Pancreatic Cancer Research

ResearcherFourth Hospital of Hebei Medical UniversityNo recent work listed

Meijie Sang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5085302395. Sources: OpenAlex.

Their work

Papers
5
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper

Papers 5

  1. Impact of RUNX2 gene silencing on the gemcitabine sensitivity of p53‑mutated pancreatic cancer MiaPaCa‑2 spheres. Co-author DOI 10.3892/or.2018.6344↗
  2. Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 … Co-author DOI 10.1371/journal.pone.0179884↗
  3. Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death. Co-author DOI 10.1038/oncsis.2016.40↗
  4. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TA… Co-author DOI 10.18632/oncotarget.12433↗
  5. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Co-author DOI 10.1038/cddiscovery.2015.10↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mizuyo Nakamura · 5 shared papers, 2015–2018 · strength 0.33
  2. Toshinori Ozaki · 5 shared papers, 2015–2018 · strength 0.33
  3. Osamu Shimozato · 5 shared papers, 2015–2018 · strength 0.33
  4. Takehiro Ogata · 3 shared papers, 2016–2018 · strength 0.22
  5. Meixiang Sang · 2 shared papers, 2016–2017 · strength 0.13
  6. Hirokazu Sugimoto · 2 shared papers, 2015–2016 · strength 0.11
  7. Hiroki Nagase · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.